Eliem Therapeutics Goodwill and Intangible Assets 2021-2024 | CLYM
Eliem Therapeutics goodwill and intangible assets from 2021 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Eliem Therapeutics Annual Goodwill and Intangible Assets
(Millions of US $) |
| 2023 |
$ |
| 2022 |
$ |
| 2021 |
$ |
| 2020 |
$ |
Eliem Therapeutics Quarterly Goodwill and Intangible Assets
(Millions of US $) |
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
|
| 2023-09-30 |
|
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
$0 |
| 2020-12-31 |
|
| 2020-09-30 |
$0 |
| 2020-06-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
